Does ENZALUTAMIDE Cause Injection site mass? 42 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Injection site mass have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.1% of all adverse event reports for ENZALUTAMIDE.
42
Reports of Injection site mass with ENZALUTAMIDE
0.1%
of all ENZALUTAMIDE reports
7
Deaths
12
Hospitalizations
How Dangerous Is Injection site mass From ENZALUTAMIDE?
Of the 42 reports, 7 (16.7%) resulted in death, 12 (28.6%) required hospitalization.
Is Injection site mass Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 42 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Injection site mass?
EXENATIDE (3,506)
DUPILUMAB (2,243)
GLATIRAMER (2,172)
ETANERCEPT (2,101)
NALTREXONE (1,849)
TIRZEPATIDE (1,386)
LEUPROLIDE (1,359)
DULAGLUTIDE (1,319)
EVOLOCUMAB (1,254)
ADALIMUMAB (915)
Which ENZALUTAMIDE Alternatives Have Lower Injection site mass Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE